BioSpace News Archive

Apollomics Inc., announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress 2023, being held in Madrid, Spain from October 20-24, 2023.

VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.

Elevar Therapeutics, Inc. today announced the hiring of Brian Cunningham as vice president of sales and Kenneth Rankin as vice president of market access.

Samsung Biologics and Kurma Partners announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a peer-reviewed article published in the Journal of Pharmaceutical & Biomedical Analysis.

Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2-expressing advanced solid tumors.

Geneoscopy Inc., a life sciences company focused on developing diagnostic tests for gastrointestinal health, announced a publication in The Journal of the American Medical Association (JAMA), highlighting the company’s pivotal CRC-PREVENT trial results. The novel study will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, Canada.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023.

Gestalt Diagnostics, Inc., a leading provider of artificial intelligence powered digital pathology solutions, and Pramana, Inc., an AI-enabled health tech company modernizing the pathology sector, announced a new integrated digital and AI-powered platform for laboratories, health systems, and academic medical centers.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference, held in Madrid, Spain (October 20 – 24, 2023).